Table of Contents

Overview

Relevance tier by entity

test

Cannot include /Template_Relevance.md - does not exist yet

Warnings

may not exist

Mutation incidence from meta-analysis

sub headings per file here unless there is just one

DLBCL

Entity Collection N mutated Incidence 95% CI
DLBCL GAMBL without Reddy 1,089 174 0.1598 [0.138,0.1815]
DLBCL GAMBL with Reddy 2,088 303 0.1451 [0.13,0.1602]
DLBCL BC 231 50 0.2165 [0.1633,0.2696]
DLBCL Dana-Farber 303 53 0.1749 [0.1321,0.2177]
DLBCL NCI 470 50 0.1064 [0.0785,0.1343]
DLBCL Reddy 999 129 0.1291 [0.1083,0.1499]
DLBCL DLBCL_ICGC 85 21 0.2471 [0.1554,0.3387]

FL

pathology Collection N mutated Incidence CI
FL GAMBL without Crouch 642 281 0.4377 [0.3993,0.4761]
FL GAMBL with Crouch 1,189 542 0.4558 [0.4275,0.4842]
FL BC 379 184 0.4855 [0.4352,0.5358]
FL Kalmbach 164 62 0.3780 [0.3038,0.4523]
FL Crouch 547 261 0.4771 [0.4353,0.519]
FL FL_ICGC 99 35 0.3535 [0.2594,0.4477]

BL

pathology Collection N mutated Incidence CI
BL GAMBL without Panea 309 1 0.0024 [0,0.0079]
BL GAMBL without ICGC/Zhou 320 2 0.0055 [0,0.0136]
BL GAMBL with Panea 410 2 0.0030 [0,0.0082]
BL BLGSP 219 1 0.0046 [0,0.0135]
BL Zhou/ICGC 90 0 0.0011 [0,0.008]
BL Panea 101 1 0.0099 [0,0.0292]

Mutation pattern and selective pressure estimates

Entity Missense dN/dS Nonsense dN/dS Q value
BL 1.4784 0 1
FL 1.1511 0 0
DLBCL 0.3993 0 0

aSHM regions

section will only exist for certain genes

chr_name hg19_start hg19_end region regulatory_comment
chr6 90981034 91016134 TSS NA

Hotspots

section will only exist for certain genes

Cannot include /Template_Browser.md - does not exist yet

Expression

Cannot include /Template_History.md - does not exist yet

References

1.
Bal E, Kumar R, Hadigol M, Holmes AB, Hilton LK, Loh JW, Dreval K, Wong JCH, Vlasevska S, Corinaldesi C, Soni RK, Basso K, Morin RD, Khiabanian H, Pasqualucci L, Dalla-Favera R. Super-enhancer hypermutation alters oncogene expression in B cell lymphoma. Nature. 2022 Jul;607(7920):808–815. PMCID: PMC9583699
2.
Burkhardt B, Michgehl U, Rohde J, Erdmann T, Berning P, Reutter K, Rohde M, Borkhardt A, Burmeister T, Dave S, Tzankov A, Dugas M, Sandmann S, Fend F, Finger J, Mueller S, Gökbuget N, Haferlach T, Kern W, Hartmann W, Klapper W, Oschlies I, Richter J, Kontny U, Lutz M, Maecker-Kolhoff B, Ott G, Rosenwald A, Siebert R, von Stackelberg A, Strahm B, Woessmann W, Zimmermann M, Zapukhlyak M, Grau M, Lenz G. Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age. Nat Commun. 2022 Jul 6;13(1):3881. PMCID: PMC9259584
3.
Sarkozy C, Hung SS, Chavez EA, Duns G, Takata K, Chong LC, Aoki T, Jiang A, Miyata-Takata T, Telenius A, Slack GW, Molina TJ, Ben-Neriah S, Farinha P, Dartigues P, Damotte D, Mottok A, Salles GA, Casasnovas RO, Savage KJ, Laurent C, Scott DW, Traverse-Glehen A, Steidl C. Mutational landscape of gray zone lymphoma. Blood. 2021 Apr 1;137(13):1765–1776.
4.
Tanaka S, Louie DC, Kant JA, Reed JC. Frequent incidence of somatic mutations in translocated BCL2 oncogenes of non-Hodgkin’s lymphomas. Blood. 1992 Jan 1;79(1):229–237.

Citing

If you use the information or data from this site, please cite

Krysta Coyle, Kostiantyn Dreval, Daniel Hodson and Ryan D. Morin. Audit of B-cell cancer genes. Blood Adv (2025) 9 (8): 2019–2031.

Disclaimer

The content in these pages has been populated, in part, by an automated process. Although we have scrutinized every page to ensure accuracy, errors will inevitably exist. If you find an error please report it as an issue and we will address it.

License

This work is licensed under a Creative Commons Attribution 4.0 International License.

You are free to:

Share — copy and redistribute the material in any medium or format for any purpose, even commercially.

Adapt — remix, transform, and build upon the material for any purpose, even commercially. The licensor cannot revoke these freedoms as long as you follow the license terms.